Repligen Co. (NASDAQ:RGEN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 30.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,991 shares of the biotechnology company's stock after selling 52,435 shares during the quarter. Principal Financial Group Inc. owned about 0.22% of Repligen worth $18,006,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RGEN. First Turn Management LLC acquired a new position in shares of Repligen during the third quarter valued at about $13,202,000. Geneva Capital Management LLC increased its stake in Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after purchasing an additional 10,908 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock worth $95,037,000 after buying an additional 36,773 shares during the last quarter. Integral Health Asset Management LLC lifted its stake in shares of Repligen by 20.0% during the second quarter. Integral Health Asset Management LLC now owns 60,000 shares of the biotechnology company's stock worth $7,564,000 after buying an additional 10,000 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Repligen during the second quarter valued at $5,320,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on RGEN shares. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating on the stock. Finally, StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $185.20.

Repligen Price Performance

Shares of Repligen stock traded down $0.24 during trading hours on Friday, reaching $145.54. The stock had a trading volume of 237,224 shares, compared to its average volume of 652,893. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.15 billion, a PE ratio of -393.34, a PEG ratio of 4.64 and a beta of 0.96. The stock's 50 day moving average is $144.52 and its 200 day moving average is $141.72.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 EPS. Equities analysts expect that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.